Join
Live feed
·
NEWSReleasevia Quantisnow
Jaguar Health Inc. logo

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

ByQuantisnow·Wall Street's wire, on your screen.
JAGX· Jaguar Health Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JAGX (Jaguar Health Inc.) and more on Quantisnow.